检索结果-南通市图书馆

Clinical imaging factors of excellent outcome after thrombolysis in large- vessel stroke: a THRACE subgroup analysis

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Stroke & Vascular Neurology 2021年第4期6卷 631-639页

作者： nolwenn Riou-Comte Benjamin Gory Marc Soudant François Zhu Yu Xie Lisa Humbertjean Gioia Mione Catherine Oppenheim Francis Guillemin Serge Bracard Sébastien Richard on behalf of the THRACE investigators Department of Neurology-Stroke Unit CIC-P 1433INSERMU1116Universitéde LorraineNancy Regional University Hospital CenterNancyFrance Department of Diagnostic and Therapeutic Neuroradiology INSERM U1254IADIUniversitéde LorraineNancy Regional University Hospital CenterNancyFrance Clinical Investigation Centre-Clinical Epidemiology 1433 INSERMUniversitéde LorraineNancy Regional University Hospital CenterNancyFrance Department of Neuroradiology INSERM U894UniversitéParis-DescartesSainte-Anne HospitalParisFrance 不详

Background For patients with stroke with large-vessel occlusion(LVO),study of factors predicting response to intravenous thrombolysis(IVT)would allow identifying subgroups with high expected gain,and those for whom it could be considered as futile,and even *** patients included in the Mechanical Thrombectomy After Intravenous Alteplase vs Alteplase Alone After Stroke trial,we investigated clinical-imaging factors associated with optimal response to *** We included patients receiving IVT *** outcome was defined by a 3-month modified Rankin Scale(mRS)score≤***-imaging predictors were assessed on multivariate analysis after multiple *** predictive performance of the model was assessed with the *** Among 247 patients with LVO treated with IVT alone,77(31%)showed 3-month mRS≤*** of 3-month mRS≤1 were no medical history of hypertension(OR 2.43;95%CI 1.74 to 3.38;p=0.007);no current smoking(OR 2.76;95%CI 1.79 to 4.26;p=0.02);onset-to IVT time(OR 0.47 per hour increase;95%CI 0.23 to 0.78;p=0.003);diffusion-weighted imaging(DWI)volume(OR 0.78 per 10 mL increase;95%CI 0.68 to 0.89;p=0.0004);presence of susceptibility vessel sign(SVS)(OR 7.89;95%CI 1.65 to 37.78;p=0.01)and SVS length(OR 0.87 per mm increase;95%CI 0.80 to 0.94;p=0.001).The prediction models showed a C-statistic=0.79(95%CI 0.79 to 0.80).Conclusions In patients with stroke with anterior-circulation LVO treated with IVT alone,predictors of excellent outcome at 3 months were no medical history of hypertension or current smoking,reduced onset-to IVT time,small DWI volume,presence of SVS and short SVS *** predictive factors could help practitioners in decision-making for IVT implementation in reperfusion strategies,all the more for the drip and ship *** registration number NCT01062698.

关键词： thrombolysis Clinical assessed

AFM Analysis on Polymer Optical Micro-Resonators: Investigation on Quality Factor Origin

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Optics and Photonics Journal 2013年第4期3卷 291-295页

作者： David Pluchon nolwenn Huby Véronique Vié Pascal Panizza Bruno Bêche 1Institute of Physics of Rennes UMR CNRS 6251 University of Rennes 1 Campus Beaulieu Rennes France 2Institut Universitaire de France-IUF Paris France Institute of Physics of Rennes UMR CNRS 6251 University of Rennes 1Campus Beaulieu Rennes France

This paper deals with the surface analysis of spherical polymeric optical micro-resonators in order to correlate surface defects with optical characteristics. Atomic force microscopy was used on structures to determine surface quality, which is the main origin of optical scattering losses. Surface morphologies were numerically treated to enable a relevant investigation on surface parameters such as root mean square (RMS) roughness (30.1 +/- 3.0 nm) or correlation length (few microns) necessary to express optical quality factors. A statistical analysis was conducted for calibration of these parameters as a function of cavities’ diameter. Results are in perfect agreement with spectral analyses performed in parallel on others structures. This comparison highlights the main role of scattering losses on quality factor origin.

关键词： Optical Micro-Resonators Quality Factor Origin Atomic Force Microscopy Surface Analysis Scattering Loss

The efficacy and safety of pramipexole ER versus IR in Chinese patients with Parkinson’s disease: a randomized, double-blind, double-dummy, parallel-group study

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Translational Neurodegeneration 2014年第1期3卷 80-88页

作者： Ying Wang Shenggang Sun Suiqiang Zhu Chunfeng Liu Yiming Liu Qing Di Huifang Shang Yan Ren Changhong Lu Mark Forrest Gordon nolwenn Juhel Shengdi Chen for the Pramipexole ER Study Team Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine ShanghaiChina Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology WuhanChina Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology WuhanChina The Second Affiliated Hospital of Soochow University SuzhouChina Qilu Hospital affiliated to Shandong University JinanChina Nanjing Brain Hospital NanjingChina West China Hospital affiliated to Sichuan University ChengduChina First Affiliated Hospital of China Medical University ShenyangChina Boehringer Ingelheim International Trading(Shanghai)Co LtdShanghaiChina Boehringer Ingelheim Pharmaceuticals IncRidgefieldCTUSA Boehringer Ingelheim France S.A.S ReimsFrance Department of Neurology Ruijin Hospital affiliated to Shanghai Jiaotong University School of MedicineShanghaiChina 不详

Objective:To evaluate the non-inferiority of pramipexole extended-release(ER)versus immediate-release(IR)in Chinese patients with Parkinson’s disease(PD)in a double-blind,randomized,parallel-group ***:Subjects were Chinese patients with idiopathic PD with diagnosis≥2 years prior to trial,age≥30 years old at diagnosis,and Modified Hoehn and Yahr score 2-4 during‘on’-*** received treatment with pramipexole ER(n=234)or IR(n=239).Non-inferiority was based on the primary endpoint,the change from baseline to end of maintenance(week 18)in the UPDRS(Parts II+III)total ***:For the primary endpoint,the adjusted mean changes(standard error)of UPDRS Parts II+III at week 18 were−13.81(0.655)and−13.05(0.643)for ER and IR formulations,respectively,using ANCOVA adjusted for treatment and centre(fixed effect)and baseline(covariate).The adjusted mean between group difference was 0.8 for the 2-sided 95%CI(−1.047,2.566).Since the lower limit of the 2-sided 95%CI(−1.047)for treatment difference was higher than the non-inferiority margin of−4,non-inferiority between pramipexole ER and IR was *** incidence of adverse events(AEs)was 68.8%in the ER arm and 73.6%in the IR arm with few severe AEs(ER:2.1%;IR:3.8%).Conclusion:Based on the UPDRS II+III score,pramipexole ER was non-inferior to pramipexole *** safety profiles of pramipexole ER and IR were *** results were based on comparable mean daily doses and durations of treatment for both formulations.

关键词： Parkinson’s disease Pramipexole ER Pramipexole IR Non-inferiority Unified Parkinson’s Disease Rating Scale(UPDRS) Safety

Silica Nano-Networks as Stretches on Segmented SU8 Rods for Sub-Wavelength Photonics

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Optics and Photonics Journal 2011年第1期1卷 11-14页

作者： Francois Doré Bruno Bêche nolwenn Huby F. Artzner Lionel Camberlein Etienne Gaviot 不详

The optical properties of CdBr2 were studied by first principle using the density functional theory. The dielectric functions and optical constants are calculated using the full potential-linearized augmented plane wave (FP-LAPW) method with the generalized gradient approximation (GGA). The theoretical calculated optical properties and energy Loss (EEL) spectrum yield a static refractive index of 2.1 and a plasmon energy of 13eV for hexagonal phase. The results, in comparison with the published data, are in good agreement with the experimental and previous theoretical results.

关键词： Optical Properties CdBr2 WIEN2k FP-LAPW DFT GGA

普拉克索缓释剂和速释剂治疗中国帕金森病患者的疗效及安全性对比评估：一项随机、双盲、双模拟平行组研究

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

中华神经科杂志 2015年第4期48卷 287-287页

作者：王瑛孙圣刚朱遂强刘春风刘艺鸣狄晴商慧芳任艳陆长虹 Mark Forrest Gordon nolwenn Juhel 陈生弟上海交通大学医学院附属瑞金医院神经内科 200025 华中科技大学同济医学院附属协和医院神经内科华中科技大学同济医学院附属同济医院神经内科苏州大学附属第二医院神经内科山东大学齐鲁医院神经内科南京脑科医院神经内科四川大学附属华西医院神经内科中国医科大学附属第一医院神经内科勃林格殷格翰国际贸易(上海)公司中国勃林格殷格翰药业公司美国勃林格殷格翰公司法国

帕金森病是一种慢性神经系统退行性疾病，主要临床表现为运动症状和非运动症状。早期帕金森病患者常应用多巴胺受体激动剂单药治疗，以延迟左旋多巴诱发的运动并发症；晚期帕金森病患者多应用左旋多巴联合多巴胺受体激动剂治疗，可减少... 详细信息

帕金森病是一种慢性神经系统退行性疾病，主要临床表现为运动症状和非运动症状。早期帕金森病患者常应用多巴胺受体激动剂单药治疗，以延迟左旋多巴诱发的运动并发症；晚期帕金森病患者多应用左旋多巴联合多巴胺受体激动剂治疗，可减少已发生的运动并发症。普拉克索速释剂和缓释剂是非麦角类多巴胺受体激动剂，对D2家族受体呈现高度选择性，对D3受体更具亲和力，显示其良好的疗效和不良反应小的优势。虽已有国际研究证实普拉克索缓释剂和速释剂的疗效，但是还没有两者对中国帕金森病患者的对比评估研究。我们对普拉克索缓释剂和速释剂联合左旋多巴治疗在中国帕金森病患者中的疗效进行非劣效性评估。

关键词：早期帕金森病普拉克索单药治疗缓释剂非麦角类多巴胺受体激动剂患者疗效速释